Savion Gropper
Overview
Explore the profile of Savion Gropper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
629
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitchell L, Roshammar D, Huang F, Albisetti M, Brandao L, Bomgaars L, et al.
Thromb Haemost
. 2022 Aug;
122(9):1573-1583.
PMID: 35909257
Background: Dabigatran etexilate, a direct oral thrombin inhibitor, is approved to treat venous thromboembolism (VTE) in both adults and children. Objectives: This population analysis characterized relationships between dabigatran total plasma...
2.
Ferrante M, Irving P, Selinger C, DHaens G, Kuehbacher T, Seidler U, et al.
Expert Opin Drug Saf
. 2022 Jul;
22(2):141-152.
PMID: 35861588
Background: Interleukin (IL)-36 signaling has been shown to be increased in ulcerative colitis (UC). Spesolimab, a novel humanized monoclonal antibody, targets the IL-36 pathway. Research Design And Methods: We report...
3.
Roshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, et al.
J Thromb Haemost
. 2021 Feb;
19(5):1259-1270.
PMID: 33636042
Background: Dabigatran etexilate (DE), a direct oral thrombin inhibitor, has been evaluated in children with venous thromboembolism (VTE) using oral solution, pellets, or capsules. Objectives: This study evaluated DE pharmacokinetics...
4.
Halton J, Brandao L, Luciani M, Bomgaars L, Chalmers E, Mitchell L, et al.
Lancet Haematol
. 2020 Dec;
8(1):e22-e33.
PMID: 33290737
Background: Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism. The aims of this clinical trial were...
5.
Brandao L, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell L, et al.
Blood
. 2019 Dec;
135(7):491-504.
PMID: 31805182
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children...
6.
Maas H, Gropper S, Huang F, Stangier J, Tartakovsky I, Brueckmann M, et al.
Thromb Haemost
. 2018 Aug;
118(9):1625-1636.
PMID: 30112751
Background: Physiological age-related changes in the haemostatic and coagulation systems result in differing anticoagulant assay responses to standard anticoagulants. Therefore, we investigated the response of anticoagulant assays to dabigatran etexilate...
7.
Luciani M, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Chalmers E, et al.
Res Pract Thromb Haemost
. 2018 Jul;
2(3):580-590.
PMID: 30046763
Background: Anticoagulant therapy for venous thromboembolism (VTE) in children is largely based on treatment recommendations for adults. However, differences in both physiology (ie, renal maturation and drug excretion) and developmental...
8.
Albisetti M, Biss B, Bomgaars L, Brandao L, Brueckmann M, Chalmers E, et al.
Res Pract Thromb Haemost
. 2018 Jul;
2(2):347-356.
PMID: 30046738
Background: The current standard of care (SOC) for pediatric venous thromboembolism (VTE) comprises unfractionated heparin (UFH), or low-molecular-weight heparin (LMWH) followed by LMWH or vitamin K antagonists, all of which...
9.
Albisetti M, Schlosser A, Brueckmann M, Gropper S, Glund S, Tartakovsky I, et al.
Res Pract Thromb Haemost
. 2018 Jul;
2(1):69-76.
PMID: 30046708
Background: The incidence of venous thromboembolism (VTE) in children has been increasing. Anticoagulants are the mainstay of treatment but are associated with bleeding events that may be life-threatening. Idarucizumab is...
10.
Tervonen T, Ustyugova A, Sri Bhashyam S, Lip G, Verdecchia P, Kwan R, et al.
Value Health
. 2017 Dec;
20(10):1394-1402.
PMID: 29241899
Background: Decision on the most appropriate oral anticoagulation therapy for stroke prevention in patients with nonvalvular atrial fibrillation is difficult because multiple treatment options are available, and these vary in...